Abstract
BackgroundSMA1 is a rapidly progressing disease resulting in muscle weakness, respiratory failure, and early death. This retrospective analysis estimated the economic burden of SMA1 using QuintilesIMS’s PharMetrics Plus Health Plan...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Neurology, Neurosurgery & Psychiatry
Paper Title
Journal
Date
